DP
ADPT icon

DDD Partners’s Adaptive Biotechnologies ADPT Stock Holding History

DDD Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,747
Closed -$388K – 103
2024
Q4 		$388K Sell
64,747
-704,419
-92% -$3.88M 0.05% 77
2024
Q3 		$3.94M Sell
769,166
-831
-0.1% -$3.62K 0.43% 41
2024
Q2 		$2.79M Buy
769,997
+30,258
+4% +$96K 0.32% 46
2024
Q1 		$2.37M Sell
739,739
-61,183
-8% -$237K 0.29% 46
2023
Q4 		$3.92M Buy
800,922
+17,225
+2% +$78.6K 0.53% 42
2023
Q3 		$3.39M Buy
+783,697
New +$5.18M 0.49% 42
2021
Q4 		– Sell
-316,927
Closed -$10.8M – 82
2021
Q3 		$10.8M Buy
316,927
+66,545
+27% +$2.41M 1.61% 26
2021
Q2 		$10.2M Buy
250,382
+140,882
+129% +$5.48M 1.55% 28
2021
Q1 		$4.41M Buy
109,500
+1,481
+1% +$80.2K 0.75% 43
2020
Q4 		$6.39M Buy
108,019
+5,071
+5% +$261K 1.26% 29
2020
Q3 		$5.01M Buy
+102,948
New +$4.33M 1.3% 25

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DDD Partners's ADPT Position: Q1 2025 in Review

DDD Partners sold out of Adaptive Biotechnologies (ADPT) in Q1 2025, closing a stake of 64,747 shares — an estimated $388K sold.

DDD Partners first reported a position in ADPT in Q3 2020 and held it in 11 quarters. The position peaked at $10.8M in Q3 2021. 225 funds tracked by Wall St. Rank hold ADPT as of Q1 2025.

  • DDD Partners reported no remaining Adaptive Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • DDD Partners sold 64,747 Adaptive Biotechnologies shares in Q1 2025, an estimated $388K.
  • DDD Partners first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 11 quarters.
  • DDD Partners's Adaptive Biotechnologies position peaked at $10.8M in Q3 2021.
  • 225 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2025.

Based on DDD Partners's 13F filing for Q1 2025, filed 2 May 2025.